ACP-319

DRUG2 trials

Sponsors

Acerta Pharma BV

Conditions

B-AllChronic Lymphocytic LeukemiaMultiple MyelomaNon-Hodgkins Lymphoma

Phase 1

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Active, not recruitingNCT02157324

Acerta Pharma BVChronic Lymphocytic Leukemia

Start: 2014-08-18End: 2026-04-01Updated: 2025-08-13

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

CompletedNCT02328014

Acerta Pharma BVB-All, Multiple Myeloma, Non-Hodgkins Lymphoma

Start: 2014-12-20End: 2025-10-30Updated: 2025-12-09

Related Papers

Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.

Journal of Clinical Oncology2018-05-206 citations